{"task_id": "ccb160c49f751b58", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 235/464)", "text": "\u2019\nJAMA 2004 292:12\n224\nHereditary Cancer Syndromes\n\n--- Page 246 ---\nBRCA SYNDROMES\nBRCA1\nBRCA2\nGenetics\nAutosomal dominant with variable penetrance, 17q21\nAutosomal dominant with variable\npenetrance, 13q13\nPathophysiology\nTumor suppressor, granin protein family with zinc\nfinger motif, packaging and export of peptide\nhormones\nTumor suppressor\nCancer types\nBreast (19% by age 40, 50% by age 50, 85% by age 70),\novarian (14 45% lifetime risk), prostate (8 16%),\ncolon (6%)\nBreast (50 85%), ovarian (<20%),\nmale breast (6%), prostate\n(8 16%)\nClinical features\nYoung age of breast cancer, bilateral breast cancer, ER\n(70%), lobular\nYoung age of breast cancer, bilateral\nbreast cancer, male breast cancer,\nlobular\nGenetic testing\n2 common mutations\n1 common mutation\nSurveillance\nBreast\nstarting at young age, clinical breast exam, mammogram, and MRI q6months\nOvarian\nscreening decision individualized\nProphylaxis\nProphylactic mastectomy\nbreast cancer risk reduction of 90%\nProphylactic oophorectomy\nwhen childbearing is complete. Breast cancer risk reduction of\n75% and ovarian cancer risk reduction of 95%\nHormonal\ntamoxifen or raloxifene are not routinely recommended, especially in BRCA1\nfamilies, where the majority of cancers are ER negative\nLI FRAUMENI SYNDROME\nGENETICS\nautosomal dominant\nPATHOPHYSIOLOGY\ntumor\nsuppressor,\np53\nmutation\nCANCER TYPES\nsoft tissue sarcoma, osteosarcoma,\nleukemia, breast, melanoma, colon, pancreas, adrenal\ncortex, brain\nVON HIPPEL LINDAU SYNDROME\nPATHOPHYSIOLOGY\nVHL mutation\nCANCER TYPES\nhemangioblastomas of the brain,\nspinal cord, retina, renal cysts, and clear cell renal cell\ncarcinoma (40%), pheochromocytomas, endolympha\ntic sac tumors of the middle ear, serous cystadenomas\nand neuroendocrine tumors of the pancreas, papillary\ncystadenomas of the epididymis and broad ligament\nHEREDITARY MALIGNANT MELANOMA\nCANCER TYPES\nmelanoma, pancreatic\nHEREDITARY DIFFUSE GASTRIC CANCER (HDGC)\nPATHOPHYSIOLOGY\nE cadherin\ngene\nCDH1\nmutation\nCANCER TYPES\ndiffuse signet ring cell type gastric,\ncolon, breast (lobular), prostate, ovary\nHEREDITARY NON POLYPOSIS COLORECTAL CANCER\n(HNPCC, LYNCH SYNDROME)\nGENETICS\nautosomal dominant\nPATHOPHYSIOLOGY\nDNA mismatch repair genes\n(hMLH1, hMSH2, hPMS1, hPMS2, hMSH6). MSH2 and\nMLH1 account for most of the mutations\nCANCER TYPES\ncolorectal (70 80% lifetime risk),\nendometrial (most common extracolonic cancer in\nwomen), small bowel, gastric, ovarian, hepatobiliary,\npancreatic, kidney, ureter, brain (Turcot\u2019s syndrome),\nskin (sebaceous adenomas \u0006 keratoacanthomas in\nthe Muir Torre variant syndrome)\nFEATURES\nfor colon cancer, predominant involve\nment of right colon, poorly differentiated, increased\nfrequency of mucinous and signet cell tumors, lym\nphocytic infiltration, MSI high (90%), and better prog\nnosis. Clinical diagnosis can be made by the Amster\ndam criteria w321w: \u00053 relatives with colorectal\ncancer (two of whom must be first degree relatives),\n\u00052 generations involved, and \u00051 family member\ndiagnosed before age 50. FAP should be excluded\nSURVEILLANCE\nfor individuals who have a mis\nmatch repair gene mutation or are strongly suspected\nof having Lynch syndrome, consider colonoscopy every\n1 2 years starting at 20 25 or 10 years earlier than the\nyoungest age of colon cancer diagnosis in the family\n(start at age 30 for MSH6 mutations) and annually after\nage 40. Annual screening for endometrial and ovarian\ncancer (pelvic examination, endometrial aspirate,\ntransvaginal U/S) beginning at age 30 35 years or\n5 10 years earlier than the earliest age of first diag\nnosis of these cancers in the family. Median age of\ndiagnosis is 48. Annual urinalysis and cytologic exam\nination beginning at age 25 35. Annual skin surveil\nlance. Periodic upper endoscopy should be considered\nPROPHYLAXIS\ntotal or subtotal colectomy with\nileorectal anastomosis for HNPCC patients with color\nectal cancer or advanced adenoma (and post surgical\nrectal surveillance). Discussion of prophylactic hyster\nectomy and salpingo oopherectomy at around age\n35 or at the end of childbearing\nHEREDITARY NON POLYPOSIS COLORECTAL CANCER\n(HNPCC, LYNCH SYNDROME) (CONT\u2019D)\nHereditary Cancer Syndromes\n225", "text_length": 4154, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 235/464)", "type": "chunk", "chunk_index": 234, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.570269", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.570958", "status": "complete", "chunks_added": 3}